Key result
Oral acyclovir reduced the mean duration of clinical symptoms from 10.1 to 3.7 days compared to placebo in patients with recurrent HSV-2 infection of the hand.
Why the study?
Does oral acyclovir reduce the duration of symptoms, signs, and viral positivity in patients with recurrent herpes simplex virus type 2 infection of the hand?
RCT (n=14)
Double-blind
Randomized to cycle A or B by a computer program
No
Does oral acyclovir reduce the duration of symptoms, signs, and viral positivity in patients with recurrent herpes simplex virus type 2 infection of the hand?
Oral acyclovir significantly reduces the duration of symptoms, signs, and viral shedding in recurrent HSV-2 infection of the hand.
Supports acyclovir for recurrent HSV-2 hand infection; extends RCT evidence to this uncommon site.
Acyclovir was evaluated as treatment of recurrent herpes simplex virus type 2 infection of the hand in a double-blind, placebo-controlled crossover study. In nine fully evaluable patients, oral acyclovir (2 g/day in three doses for 10 days) initiated during the earliest phase of a recurrence reduced the mean durations (+/- standard deviation) of clinical symptoms from 10.1 (+/- 3.6) to 3.7 (+/- 3.0) days (P = 0.008), signs from 11.1 (+/- 3.7) to 6.2 (+/- 3.3) days (P = 0.024), and viral positivity from 5.3 (+/- 3.8) to 0.6 (+/- 1.1) days (P = 0.011).
No takes yet. Share an insight, caveat, or question.
Gill et al. (1991) conducted an RCT in Recurrent herpes simplex virus type 2 (HSV-2) infection of the hand (n=14). Oral acyclovir vs. Placebo was evaluated on Mean duration of clinical symptoms (p=0.008). Oral acyclovir reduced the mean duration of clinical symptoms from 10.1 to 3.7 days compared to placebo in patients with recurrent HSV-2 infection of the hand.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: